Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity
Autore:
Cozzi, F; Marson, P; Rosada, M; De Silvestro, G; Bullo, A; Punzi, L; Todesco, S;
Indirizzi:
Univ Padua, Div Rheumatol, I-35128 Padua, Italy Univ Padua Padua Italy I-35128 adua, Div Rheumatol, I-35128 Padua, Italy Azienda Osped Padova, Blood Transfus Serv, Padua, Italy Azienda Osped Padova Padua Italy ova, Blood Transfus Serv, Padua, Italy
Titolo Testata:
TRANSFUSION AND APHERESIS SCIENCE
fascicolo: 1, volume: 25, anno: 2001,
pagine: 25 - 31
SICI:
1473-0502(200108)25:1<25:LTWPEI>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOLUBLE INTERLEUKIN-2 RECEPTOR; SCLERODERMA FIBROBLASTS; COLLAGEN-SYNTHESIS; III PROCOLLAGEN; EXPRESSION; ADHESION; PLASMAPHERESIS; IDENTIFICATION; PATHOGENESIS; INVOLVEMENT;
Keywords:
plasma-exchange; systemic sclerosis; aminoterminal type III procollagen; interleukin 2 soluble receptor; TDR plus cells;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Cozzi, F Univ Padua, Div Rheumatol, Via Giustiniani 2, I-35128 Padua, Italy Univ Padua Via Giustiniani 2 Padua Italy I-35128 28 Padua, Italy
Citazione:
F. Cozzi et al., "Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity", TRANSF AP S, 25(1), 2001, pp. 25-31

Abstract

Plasma exchange (PEX) is a technique that has been applied to the treatment of many immunological disorders, including connective tissue diseases. The crucial role of some humoral factors in the pathogenesis of systemic sclerosis (SSc) could explain the good clinical results obtained in terms of slowing down the disease progression, but the efficacy of PEX in the treatment of SSc is not yet well defined, owing to the lack of controlled studies and validated parameters of disease activity. To demonstrate the long-term efficacy of PEX in the treatment of SSc we treated a group of 28 SSc patients affected with recent onset and/or rapidly progressive disease. Most of these had a diffuse form of SSc, with anti-Sc170 antibody as a disease marker. Before and after long-term PEX treatment we evaluated disease activity parameters including the serum levels of interleukin 2 soluble receptor (sIL-2R) and aminoterminal type III procollagen peptide (PIIINP), plus the percentage of DR+ T cells in the peripheral blood. We also assessed clinical parameters of total skin score and total visceral score. The same parameters were evaluated in 25 SSc patients who did not satisfy the admission criteria for PEX, treated longterm with drugs only. At baseline, serum PIIINP and sIL-2R levels and the percentage of DR+ T cells were significantly increased in PEX patients as compared to others. Following long-term PEX treatment, all the laboratory parameters significantlydecreased and the clinical scores showed a slight but not significant improvement. Conversely, in the other group of SSC patients treated for the same period with drugs only, no significant change of laboratory parameters was detected and the clinical scores slightly worsened. Our data suggest that long-term PEX therapy seems to be effective in slowing down the clinical course of patients with severe and rapidly progressiveSSc. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 12:28:26